ArticleMolecular and cellular pediatrics2026
Preventive application of lung growth factors and lack of attenuation of phenotype disruption of lung resident MSC from preterm infants by hyperoxia.
Article in Molecular and cellular pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhenotype disruption of lung resident mesenchymal stem cells (MSC) is a key event in the pathogenesis of bronchopulmonary dysplasia (BPD). Hyperoxia (HOX) constitutes one major harmful factor resulting in growth arrest and changes of functional properties including downregulation of PDGFRα. FGF-10, HGF, IGF-1 and PDGF-AA constitute promising cytokines to preserve lung growth. We studied their preventive application before HOX exposure of MSC cultures.
resultsAs described before, HOX inhibited spontaneous proliferation of MSC and induced cell death. Growth inhibition was larger at HOX80% than at HOX40%. The one-time preventive application of FGF-10, HGF, IGF-1 or PDGF-AA in therapeutic dosage or the repetitive application during HOX (40% or 80%) did not attenuate the growth inhibition and cell death induction by HOX even during the milder HOX40% exposure. Furthermore, the phenotype disruption with downregulation of PDGFRα as critical hallmark event remained unchanged.
conclusionOur data indicate that the deleterious effects of HOX to lung resident MSC are that pronounced that single lung growth promoting cytokines cannot attenuate their phenotype disruption, growth inhibition and cell death by HOX. The results demand focus on MSC functionality when the therapeutic potential of lung growth promoting factors and other therapeutics intended to prevent BPD is studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.